Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma

NCT05565807 is registered in ClinicalTrials.gov with Zhejiang ACEA Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT05565807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05565807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 9, 2023
Completion date
February 19, 2028
Enrollment
84 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma